ABL ABL ABL Bio-Marker Composition for Sensitivity Prediction of ABL Drug Estimation Method for Sensitivity Prediction of ABL Drug using Bio-Marker Composition and Diagnosing Chip for Detection of Bio-Marker Composition for Sensitivity Prediction of ABL Drug

摘要

The present invention relates to a biomarker composition for determining ABL drug reactivity by using a cancer biomarker labeling scan (GBLscan), which is a new learning model in which a haplotype biomarker including ABL drug reactivity function information is predicted and thus ABL drug reactivity can be reliably predicted and drug-labeled, wherein the biomarker composition is composed of a combination of markers including variation for adjusting gene expression, so as to determine reactivity with respect to an ABL drug. The biomarker composition includes 15_59223315_G_A (marker 1) and 13_30465849_T_C (marker 2). According to the present invention, sensitivity for each genetic trait of a subject can be predicted with respect to an ABL drug through biomarkers for ABL-related drugs, and thus preliminary verification effective for discovery of a new drug candidate group as well as the field of personalized medicine can be performed.